Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Collegium Pharmaceutical management to meet virtually with Piper Sandler » 04:55
03/05/21
03/05
04:55
03/05/21
04:55
COLL

Collegium Pharmaceutical

$21.76 /

-0.155 (-0.71%)

Virtual Meeting to be…

Virtual Meeting to be held on March 5 hosted by Piper Sandler.

ShowHide Related Items >><<
COLL Collegium Pharmaceutical
$21.76 /

-0.155 (-0.71%)

COLL Collegium Pharmaceutical
$21.76 /

-0.155 (-0.71%)

01/11/21 H.C. Wainwright
Collegium Pharmaceutical price target raised to $33 from $29 at H.C. Wainwright
12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
07/14/20 BWS Financial
Collegium Pharmaceutical initiated with a Sell at BWS Financial
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
COLL Collegium Pharmaceutical
$21.76 /

-0.155 (-0.71%)

Conference/Events
Collegium Pharmaceutical management to meet virtually with Piper Sandler » 12:25
03/04/21
03/04
12:25
03/04/21
12:25
COLL

Collegium Pharmaceutical

$21.71 /

-0.2 (-0.91%)

Virtual Meeting to be…

Virtual Meeting to be held on March 5 hosted by Piper Sandler.

ShowHide Related Items >><<
COLL Collegium Pharmaceutical
$21.71 /

-0.2 (-0.91%)

COLL Collegium Pharmaceutical
$21.71 /

-0.2 (-0.91%)

01/11/21 H.C. Wainwright
Collegium Pharmaceutical price target raised to $33 from $29 at H.C. Wainwright
12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
07/14/20 BWS Financial
Collegium Pharmaceutical initiated with a Sell at BWS Financial
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
COLL Collegium Pharmaceutical
$21.71 /

-0.2 (-0.91%)

Earnings
Collegium Pharmaceutical backs Xtampza ER revenue range$155M-$165M  16:25
02/25/21
02/25
16:25
02/25/21
16:25
COLL

Collegium Pharmaceutical

$26.04 /

-0.16 (-0.61%)

 
ShowHide Related Items >><<
COLL Collegium Pharmaceutical
$26.04 /

-0.16 (-0.61%)

COLL Collegium Pharmaceutical
$26.04 /

-0.16 (-0.61%)

01/11/21 H.C. Wainwright
Collegium Pharmaceutical price target raised to $33 from $29 at H.C. Wainwright
12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
07/14/20 BWS Financial
Collegium Pharmaceutical initiated with a Sell at BWS Financial
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
COLL Collegium Pharmaceutical
$26.04 /

-0.16 (-0.61%)

Earnings
Collegium Pharmaceutical reports Q4 EPS 20c, consensus 29c » 16:23
02/25/21
02/25
16:23
02/25/21
16:23
COLL

Collegium Pharmaceutical

$26.04 /

-0.16 (-0.61%)

Reports Q4 revenue…

Reports Q4 revenue $76.3M, consensus $77.41M. "Our differentiated pain portfolio performed well during the fourth quarter, laying the groundwork for a strong start in the new year," said Joe Ciaffoni, President and Chief Executive Officer of Collegium. "As we turn to 2021, we are encouraged by underlying trends in our business and remain focused on maximizing the potential of our portfolio and creating value for our shareholders. As always, we are committed to being the leader in responsible pain management and will continue to prioritize the health and safety of our people, customers and the communities that we serve." "The fourth quarter capped a financially transformative 2020 for Collegium, in which Xtampza ER growth and the acquisition of the Nucynta franchise enabled us to deliver profitability and generate significant cash flows," said Paul Brannelly, Executive Vice President and Chief Financial Officer of Collegium. "Our 2021 outlook is supported by early Xtampza ER growth trends, expected stable profit contributions from the Nucynta franchise and our ability to continue to leverage our cost structure. This year we are focused on profitability, strong cash generation and remaining focused and disciplined in our approach to capital allocation."

ShowHide Related Items >><<
COLL Collegium Pharmaceutical
$26.04 /

-0.16 (-0.61%)

COLL Collegium Pharmaceutical
$26.04 /

-0.16 (-0.61%)

01/11/21 H.C. Wainwright
Collegium Pharmaceutical price target raised to $33 from $29 at H.C. Wainwright
12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
07/14/20 BWS Financial
Collegium Pharmaceutical initiated with a Sell at BWS Financial
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
COLL Collegium Pharmaceutical
$26.04 /

-0.16 (-0.61%)

Hot Stocks
Collegium Pharmaceutical to replace Iridium in S&P 600 at open on 2/12  04:55
02/12/21
02/12
04:55
02/12/21
04:55
COLL

Collegium Pharmaceutical

$25.08 /

-0.855 (-3.30%)

, IRDM

Iridium

$46.13 /

-1.36 (-2.86%)

 
ShowHide Related Items >><<
IRDM Iridium
$46.13 /

-1.36 (-2.86%)

COLL Collegium Pharmaceutical
$25.08 /

-0.855 (-3.30%)

COLL Collegium Pharmaceutical
$25.08 /

-0.855 (-3.30%)

01/11/21 H.C. Wainwright
Collegium Pharmaceutical price target raised to $33 from $29 at H.C. Wainwright
12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
07/14/20 BWS Financial
Collegium Pharmaceutical initiated with a Sell at BWS Financial
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
IRDM Iridium
$46.13 /

-1.36 (-2.86%)

02/08/21 Raymond James
Iridium downgraded to Market Perform from Outperform at Raymond James
02/08/21 Raymond James
Iridium downgraded to Market Perform from Outperform at Raymond James
01/20/21 BWS Financial
Iridium downgraded to Neutral from Buy at BWS Financial
12/16/20 BWS Financial
Iridium GMDSS launch 'an incremental positive,' says BWS Financial
IRDM Iridium
$46.13 /

-1.36 (-2.86%)

COLL Collegium Pharmaceutical
$25.08 /

-0.855 (-3.30%)

Hot Stocks
Collegium Pharmaceutical to replace Iridium in S&P 600 at open on 2/12  17:20
02/08/21
02/08
17:20
02/08/21
17:20
COLL

Collegium Pharmaceutical

$23.67 /

-0.6 (-2.47%)

, IRDM

Iridium

$54.33 /

+0.565 (+1.05%)

 
ShowHide Related Items >><<
IRDM Iridium
$54.33 /

+0.565 (+1.05%)

COLL Collegium Pharmaceutical
$23.67 /

-0.6 (-2.47%)

COLL Collegium Pharmaceutical
$23.67 /

-0.6 (-2.47%)

01/11/21 H.C. Wainwright
Collegium Pharmaceutical price target raised to $33 from $29 at H.C. Wainwright
12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
07/14/20 BWS Financial
Collegium Pharmaceutical initiated with a Sell at BWS Financial
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
IRDM Iridium
$54.33 /

+0.565 (+1.05%)

02/08/21 Raymond James
Iridium downgraded to Market Perform from Outperform at Raymond James
02/08/21 Raymond James
Iridium downgraded to Market Perform from Outperform at Raymond James
01/20/21 BWS Financial
Iridium downgraded to Neutral from Buy at BWS Financial
12/16/20 BWS Financial
Iridium GMDSS launch 'an incremental positive,' says BWS Financial
IRDM Iridium
$54.33 /

+0.565 (+1.05%)

COLL Collegium Pharmaceutical
$23.67 /

-0.6 (-2.47%)

Over a quarter ago
Recommendations
Collegium Pharmaceutical price target raised to $33 from $29 at H.C. Wainwright » 06:29
01/11/21
01/11
06:29
01/11/21
06:29
COLL

Collegium Pharmaceutical

$21.66 /

-0.95 (-4.20%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Oren Livnat raised the firm's price target on Collegium Pharmaceutical to $33 from $29 and reiterates a Buy rating on the shares.

ShowHide Related Items >><<
COLL Collegium Pharmaceutical
$21.66 /

-0.95 (-4.20%)

COLL Collegium Pharmaceutical
$21.66 /

-0.95 (-4.20%)

12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
07/14/20 BWS Financial
Collegium Pharmaceutical initiated with a Sell at BWS Financial
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Collegium Pharmaceutical initiated with a Neutral at Guggenheim
COLL Collegium Pharmaceutical
$21.66 /

-0.95 (-4.20%)

Hot Stocks
Collegium Pharmaceutical sees FY21 adjusted EBITDA $160M-$170M » 16:11
01/06/21
01/06
16:11
01/06/21
16:11
COLL

Collegium Pharmaceutical

$20.62 /

+1.38 (+7.17%)

Xtampza ER revenues are…

Xtampza ER revenues are expected in the range of $155M to $165M. Nucynta franchise revenues are expected in the range of $175M to $185M. Adjusted EBITDA is expected in the range of $160M to $170M. Total operating expenses are expected in the range of $125M to $135M. "Collegium achieved a financially transformative year in 2020, driven by Xtampza ER growth and the acquisition of the Nucynta franchise. We delivered on our broad operational objectives and prioritized the health and safety of our people, customers and the communities that we serve," said Joe Ciaffoni, president and CEO of Collegium. "As we head into 2021, we remain steadfast in our commitment to being the leader in responsible pain management, maximizing the potential of our differentiated pain portfolio and creating value for our shareholders." "Our 2021 revenue outlook is supported by Xtampza ER growth, stable profit contribution from the Nucynta franchise and a commitment to leverage our cost structure," said Paul Brannelly, CFO of Collegium. "This year, we expect to generate significant cash flow from operations and will deploy our balance sheet in a disciplined manner that invests in the long-term growth of our company."

ShowHide Related Items >><<
COLL Collegium Pharmaceutical
$20.62 /

+1.38 (+7.17%)

COLL Collegium Pharmaceutical
$20.62 /

+1.38 (+7.17%)

12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
07/14/20 BWS Financial
Collegium Pharmaceutical initiated with a Sell at BWS Financial
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Collegium Pharmaceutical initiated with a Neutral at Guggenheim
COLL Collegium Pharmaceutical
$20.62 /

+1.38 (+7.17%)

Recommendations
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List » 07:35
12/29/20
12/29
07:35
12/29/20
07:35
COLL

Collegium Pharmaceutical

$18.94 /

+0.45 (+2.43%)

, RVNC

Revance

$27.88 /

+0.26 (+0.94%)

Needham analyst Serge…

Needham analyst Serge Belanger named Collegium Pharmaceutical (COLL) as his 2021 best idea and added the company to Needham Conviction List in place of Revance Therapeutics (RVNC), which was removed. The analyst is also keeping his Buy rating and $34 price target on Collegium. Belanger states that the growth prospects of the company's Xtampza within the "complex" opioid market remains its "key value driver" with significant sales growth expected next year, but the investment story has grown to include its "stabilized" Nucynta franchise. The analyst believes that Nucynta could contribute to Collegium's top-line growth and a "leverageable" cost structure that will further improve the company's profitability and cash generation.

ShowHide Related Items >><<
RVNC Revance
$27.88 /

+0.26 (+0.94%)

COLL Collegium Pharmaceutical
$18.94 /

+0.45 (+2.43%)

COLL Collegium Pharmaceutical
$18.94 /

+0.45 (+2.43%)

07/14/20 BWS Financial
Collegium Pharmaceutical initiated with a Sell at BWS Financial
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Collegium Pharmaceutical initiated with a Neutral at Guggenheim
03/23/20 Truist
SunTrust lowers price targets among Pharmaceuticals due to COVID-19
RVNC Revance
$27.88 /

+0.26 (+0.94%)

11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
10/15/20 H.C. Wainwright
Revance price target raised to $33 from $27 at H.C. Wainwright
RVNC Revance
$27.88 /

+0.26 (+0.94%)

COLL Collegium Pharmaceutical
$18.94 /

+0.45 (+2.43%)

RVNC Revance
$27.88 /

+0.26 (+0.94%)

Hot Stocks
Synlogic appoints Collegium Pharmaceutical chairman Michael Heffernan to board » 06:34
12/09/20
12/09
06:34
12/09/20
06:34
SYBX

Synlogic

$2.29 /

+0.04 (+1.78%)

, COLL

Collegium Pharmaceutical

$19.25 /

-0.33 (-1.69%)

Synlogic (SYBX) announced…

Synlogic (SYBX) announced the appointment of Michael Heffernan to its board of directors. Heffernan has over 25 years of experience building and leading development stage and commercial companies. He is the founder and chairman of the board of Collegium Pharmaceutical (COLL) where he served as president and CEO until June 2018. He co-founded Avenge Bio, an immuno-oncology company that he is actively managing, and was previously CEO of Onset Dermatologics, a dermatology company that he founded and spun out of Collegium to create PreCision Dermatology, which was later sold to Valeant.

ShowHide Related Items >><<
SYBX Synlogic
$2.29 /

+0.04 (+1.78%)

COLL Collegium Pharmaceutical
$19.25 /

-0.33 (-1.69%)

SYBX Synlogic
$2.29 /

+0.04 (+1.78%)

09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
03/30/20 Piper Sandler
Synlogic's SYNB1819 Phase 1 enrollment slowed by COVID-19, says Piper Sandler
01/09/20 Piper Sandler
Piper Sandler reiterated Buy on Synlogic after 2020 program outlook
COLL Collegium Pharmaceutical
$19.25 /

-0.33 (-1.69%)

07/14/20 BWS Financial
Collegium Pharmaceutical initiated with a Sell at BWS Financial
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Collegium Pharmaceutical initiated with a Neutral at Guggenheim
03/23/20 Truist
SunTrust lowers price targets among Pharmaceuticals due to COVID-19
SYBX Synlogic
$2.29 /

+0.04 (+1.78%)

COLL Collegium Pharmaceutical
$19.25 /

-0.33 (-1.69%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.